53 results about "Arterial velocity" patented technology

The invention relates to the technical field of health status assessment, in particular to a cardiovascular disease layered early warning system, which is characterized in that blood vessel compliance and pulse wave velocity are extracted, arterial dilation capacity is measured, blood vessel elasticity is calculated, blood perfusion distribution is detected, and abnormal vasoconstriction is classified on the basis of a hemodynamic state and a heart electrical activity state; in combination with the thickness of the blood vessel wall and the blood vessel stenosis rate, the plaque deposition condition is analyzed, the arteriosclerosis score is calculated, the thrombosis tendency is detected, the local blood flow blocking degree is quantified, the isolation forest algorithm is adopted, the blood flow dynamic change is calculated, the heart rhythm abnormality is analyzed, the acute vascular occlusion probability is measured, and the sudden heart rhythm abnormality risk is evaluated. And based on a gradient boosting tree algorithm, screening high-risk cases, matching medical intervention measures, setting a risk buffer mechanism, adjusting an individual health management strategy, and optimizing a cardiovascular risk hierarchical early warning system.

The invention provides an old people body health early diagnosis and risk assessment system based on artificial intelligence, and relates to the technical field of old people health monitoring and assessment. Old people health parameters are collected in real time according to a set time interval, and a statistical method is used to calculate a mean value and a standard deviation of cardiovascular parameters; then, based on acceleration data, heart rate change, blood pressure fluctuation and position change information, sleep, movement and resting states of the old people are judged, and the day and night blood pressure change rate, the sleep state heart rate standard deviation, the movement state pulse wave conduction speed change quantity and the resting state heart stroke output average value are calculated; four risk assessment formulas of blood pressure risk, heart rate risk, pulse wave conduction velocity risk and heart stroke output quantity are constructed according to the data, a comprehensive health risk value is calculated through weighted merging, and the health state of the old people is judged to be healthy, medium-low risk or high risk according to a set threshold value.

An advanced cardiovascular health monitoring system utilizes an optical pulse wave velocity detection device in combination with a system for analyzing data waveforms structures in combination with personalized patient data integration to determine specific physiological parameters for monitoring and assessing specific health conditions. Using acceleration pulse waves, vascular health is calculated by the ratio of peak to the second derivative of blood volume pulse wave, which can detect various health indices such as vascular age, vascular health index, and arteriosclerosis. The device collects separate pulse points within a time interval. It connects them into a line to form the PPG Image, which is then analyzed through data filtering and fitting methods. The periodic cycle acquisition method excludes abnormal cycle data and ensures correct data acquisition. Artificial Intelligence and data analytics are aiding the software to improve and optimize underlying data ranges continuously; the algorithms are summarized in figures. The invention may be used as part of non-invasive screening testing.

Pulse wave velocity (PWV) is a measure of arterial stiffness and a cardiovascular disease risk factor. Accurate PWV estimation is difficult due to complex arterial dynamics, such as longitudinal motion and natural tissue oscillations. This present disclosure relates to a robust, motion-resistant PWV estimation framework including: 1) tracking and compensating for arterial longitudinal wall motions, 2) suppressing undulating arterial motion via common mode rejection, and 3) enhancing differential signals to extract wall expansion. In vitro experiments with induced lateral motion indicate the framework's PWV estimates (6.19±0.33 m / s) closely matched reference values (6.26±0.12 m / s; error: 1.1%), outperforming methods without motion compensation (4.46±1.78 m / s; error: 28.8%). In vivo trials with five healthy subjects showed an average PWV of 4.18±0.56 m / s using the motion-resistant method, compared to 2.54±0.95 m / s without motion compensation (p<0.005). This framework enhances PWV estimation reliability, offering clinical potential for better arterial stiffness assessment and cardiovascular risk stratification.

A system and method for measuring pulse wave velocity. In some embodiments, a system includes: a pulse timing sensor, including: a first wearable speckleplethysmography sensor; and a second wearable speckleplethysmography sensor, the first wearable speckleplethysmography sensor being configured to measure a blood flow velocity at a first point, on a first artery, and the second wearable speckleplethysmography sensor being configured to measure a blood flow velocity at a second point on a second artery.

The present invention relates to a weighing scale (100) for monitoring biometric data of a user (180). The weighing scale (100) comprises a first set and a second set of multiple electrodes disposed on one or more handles (120) for making contact with a first hand and a second hand of the user (180). The weighing scale (100) further comprises a base (140) for supporting the user (180) and determining a weight of the user (180). A first portion of a top surface of the base (140) comprises a third set of multiple electrodes for making contact with a first foot of the user (180) and a second portion of the top surface of the base (140) comprises a fourth set of multiple electrodes for making contact with a second foot of the user (180). The weighing scale (100) further comprises processing circuitry for obtaining a plurality of biometric signals and determining a pulse wave velocity (PWV) of the first hand and the second hand and the first foot and the second foot of the user (180) based on the plurality of biometric signals to estimate a peripheral arterial disease (PAD) risk of the user (180).

An electronic device according to an embodiment may include communication circuitry and at least one processor. The at least one processor may be configured to receive a first PPG signal obtained by a first wearable device from the first wearable device via the communication circuitry and receive a second PPG signal from a second wearable device. The first wearable device may be worn on a first position of a user and the second wearable device may be worn on a second position of the user. The at least one processor may be configured to obtain a pulse transit time (PTT) taken for a pulse wave to be transferred from the first position to the second position, based on the first PPG signal and the second PPG signal. The at least one processor may be configured to obtain a distance between the first wearable device and the second wearable device. The at least one processor may be configured to obtain a pulse wave velocity (PWV) at which the pulse wave is transferred, based on the distance and the PTT. The at least one processor may be configured to obtain a first blood pressure by using a pulse wave analysis (PWA) method, based on the first PPG signal and / or the second PPG signal. The at least one processor may be configured to obtain a vascular characteristic value related to a characteristic of a blood vessel, based on the PWV and the first blood pressure. The at least one processor may be configured to obtain a blood pressure correction value for correcting a second blood pressure to be obtained, based on the vascular characteristic value.

The present invention relates to a composition comprising a complex extract of Coptis japonica, Phellodendron Chinensis, Scutellaria baicalensis, Gardenia jasminoides, and Rheum palmatum. The composition was confirmed to: reduce the levels of blood cholesterol, blood lipids, and blood LDL-cholesterol in patients with dyslipidemia; reduce systolic blood pressure without affecting diastolic blood pressure and pulse rate in patients with hypertension; reduce the level of pulse wave velocity (PWV), which is an indicator of arteriosclerosis, in patients with atherosclerosis, and inhibit the recurrence rate for up to 5 years in patients with cerebral infarction. Accordingly, the composition is provided as a therapeutic agent for dyslipidemia, hypertension, arteriosclerosis, or cerebral infarction. In particular, the composition is made into an encapsulated form rather than conventional decoctions, to reduce the content of geniposide, which is reported as a side effect component, and thus an optimal composition which maintains efficacy against dyslipidemia and does not cause side effects is provided.

An intravascular ultrasound transducer assembly for monitoring stiffness of a vessel wall. The assembly comprises a catheter shaft sized and shaped for insertion inside a vessel having a vessel wall and one or more intravascular devices integrated on the catheter shaft. The one or more intravascular devices are configured to monitor at least one of i) at least one anatomic structure of the vessel wall in response to a pulse wave being launched on the vessel wall so that a pulse wave velocity is determined, by operating in a pulse echo mode to track the at least one anatomic structure, and ii) signals indicative of an ambient pressure of the ultrasound transducer assembly, wherein the ambient is defined by a balloon encapsulating one of the one or more intravascular devices. The pulse wave velocity and the ambient pressure are related to, i.e., proportional to, the stiffness of the vessel wall.

The present application relates to electronic technology. Provided are a data processing method, an electronic device, a wearable device and a communication system, which are used for monitoring a physiological parameter of a user in real time, prompting the user to cooperate to input related data upon detecting that the physiological parameter is abnormal, and performing related detection. The method is applied to an electronic device, and the electronic device establishes a connection with a wearable device. The method comprises: when a wearable device is worn on a body part of a user, acquiring, on the basis of a connection, a first parameter value corresponding to a preset physiological parameter, which is collected from the user by means of the wearable device, wherein the preset physiological parameter comprises at least one of the following: a pulse wave velocity (PWV), a heart rate, a heart rate variability (HRV), a blood pressure and a respiratory rate; analyzing the first parameter value to obtain a first analysis result; and when the first analysis result represents that the preset physiological parameter of the user is abnormal, sending first prompt information, wherein the first prompt information is used for prompting the user to cooperate to input preset data, so as to perform new analysis on the preset physiological parameter.

The invention pertains to a device designed for non-invasive monitoring of blood pressure by measuring changes in blood volume within a subject's tissue. The device includes multiple light sources and photodiodes, organized into groups. Each group consists of at least one light source and multiple photodiodes placed at various distances from the light source. This configuration allows for the detection of reflected light that carries photoplethysmography (PPG) signals from different depths within the tissue. The device features a processing unit that processes the PPG signals to perform signal separation analysis, distinguishing the signals from various tissue depths. The processing unit also calculates pulse wave velocity (PWV) by examining the time difference between detections at photodiodes located at different distances. This PWV is subsequently used to estimate the subject's blood point pressure using a predetermined correlation between PWV and blood pressure.

A smart ring (104) for detecting atrial fibrillation using photoplethysmography is disclosed The smart ring (104) includes a PPG sensor for gathering PPG signals corresponding to the blood flow data of the user (102). A user device (106) receives the blood flow data and extracts a plurality of features from the blood flow data including time between heartbeats (RR intervals), variability in RR intervals, absence of P waves, presence of rapid and irregular heartbeat, SpO2, amplitude and width of the peaks, harmonic components of PPG, pulse wave velocity, etc. A weightage is assigned to each of the features. Further, the user device (106) implements a machine learning model (166) to detect a probability of occurrence of AFib based on the blood flow data. The user device (106) may further notify the user (102) about the probability of occurrence of AFib.

Some disclosed devices include a light source system, an ultrasonic receiver system and a control system. The control system may be configured to receive first sensor signals, including ultrasonic receiver signals, from the ultrasonic receiver system and to estimate one or more blood vessel features based on the first sensor signals. The control system may be configured to receive second sensor signals from a second sensor and to estimate a PWV based on the first sensor signals and the second sensor signals. The control system may be configured to estimate blood pressure based, at least in part, on the one or more blood vessel features and the PWV.

The present invention discloses a nucleic acid molecule for inhibiting PNO1 gene expression, as well as related products and uses. The nucleic acid molecule comprises double-stranded RNA or shRNA. The present invention utilizes an RNAi method to obtain siRNA, or a nucleic acid construct, viral particle, or cell containing the siRNA sequence. By downregulating PNO1 gene expression, the siRNA can effectively inhibit and significantly reduce systolic blood pressure, diastolic blood pressure, mean arterial pressure, pulse wave velocity, and vascular wall thickness in the abdominal aorta, thereby preventing and / or treating hypertension. The siRNA can be used in drugs for treating hypertension, opening up new avenues for hypertension treatment.

Provided are apparatuses and methods for non-invasively measuring a blood pressure of a mammal subject. The apparatus includes a first sensor system and a second sensor system time-synchronized to each other and spatially separated by a pulse arrival distance L, and a microcontroller unit (MCU). The first and second sensor systems are respectively attached to first and second positions of the mammal subject for detecting first and second signals. The second position is more distal or proximal to a heart of the mammal subject than the first position. The MCU processes the output signals to determine a pulse arrival time (PAT) as a time delay Δt between detections of the first and second signals, and determines a pulse wave velocity (PWV) based on the PAT and L, wherePWV=LΔ⁢⁢t.Then the MCU determines the blood pressure P from the PWV, where P is a parabolic function of the PWV.

To provide a sensor unit capable of easily calculating a pulse wave propagation speed as compared to a case where a sensor is attached to a plurality of parts of a body surface.SOLUTION: A sensor unit includes: a flexible support body; a core material that is mounted to at least a part of the flexible support body; a long sensor that is arranged in the core material; an acquisition part that acquires a plurality of output waves from an output signal derived from a heart rate, the output signal being emitted from the sensor when a shape change of at least one part of a body surface is transmitted to the sensor; and a calculation part that calculates a pulse wave propagation speed from a difference in a reference time of the output wave calculated from arithmetic processing on the plurality of output waves.SELECTED DRAWING: Figure 3

Pulse wave velocity (PWV) is a measure of arterial stiffness and a cardiovascular disease risk factor. Accurate PWV estimation is difficult due to complex arterial dynamics, such as longitudinal motion and natural tissue oscillations. This present disclosure relates to a robust, motion-resistant PWV estimation framework including: 1) tracking and compensating for arterial longitudinal wall motions, 2) suppressing undulating arterial motion via common mode rejection, and 3) enhancing differential signals to extract wall expansion. In vitro experiments with induced lateral motion indicate the framework's PWV estimates (6.19±0.33 m / s) closely matched reference values (6.26±0.12 m / s; error: 1.1%), outperforming methods without motion compensation (4.46±1.78 m / s; error: 28.8%). In vivo trials with five healthy subjects showed an average PWV of 4.18±0.56 m / s using the motion-resistant method, compared to 2.54±0.95 m / s without motion compensation (p<0.005). This framework enhances PWV estimation reliability, offering clinical potential for better arterial stiffness assessment and cardiovascular risk stratification.

The present invention relates to determining a flow profile in an artery from ultrasound imaging data. To this end, a computer-implemented method is provided for determining a flow profile based on arterial measurements, intra-arterial velocities, and asymmetry measures, the arterial measurements, intra-arterial velocities, and asymmetry measures determined from ultrasound imaging data, including B-mode, pulsed wave Doppler, and color or power Doppler ultrasound imaging data.

A system and method for contactless determination of pulse-transit time from a received image sequence. The method including: determining hemoglobin concentration (HC) signals over time at a first region of interest (ROI) and a second ROI, the first ROI and the second ROI forming a pair of ROIs, the second ROI located downstream from the first ROI along a common pulse wave path; determining a pulse transit time based on a time difference between peaks in the HC signals; and outputting the pulse transit time. The method can further include determining pulse wave velocity (PWV) using the determined PTT and a distance between the pair of ROIs, and outputting the determined PWV. The method can further include determining an estimate of blood pressure using the determined PWV with a trained machine learning model, and outputting the determined estimate of blood pressure.

The application discloses a parameter self-adaptive configuration ultrasonic carotid artery local pulse wave velocity estimation method, the method adopts a tracking section minimum variance total sum and a maximum linear fitting optimization coefficient criterion as a condition to establish a multi-objective function, optimizes and configures a pulse wave filter and a delay time estimation parameter by using a meta-heuristic algorithm, and finally calculates the carotid artery local pulse wave velocity based on the optimal parameter. The parameter self-adaptive configuration ultrasonic carotid artery local pulse wave velocity adaptive estimation is realized, the problem that the pulse wave velocity estimation is inaccurate due to the difficulty in accurately grasping the parameter in the ultrasonic carotid artery pulse wave velocity estimation process is solved, the universality of the pulse wave section parameter selection is improved, and the precision of the pulse wave velocity estimation is improved.

The present invention relates to a method for determining a pulse wave velocity and / or a pulse transit time of a patient. The method comprises receiving at least two seismocardiograms of the patient, wherein each seismocardiogram at least partially comprises a heartbeat of the patient and determining a first seismocardiogram template, wherein the first seismocardiogram template is at least partially based on the at least two seismocardiograms. The method further comprises determining a time shift with respect to the first seismocardiogram template for each of the at least two seismocardiograms, shifting each of the at least two seismocardiograms based on the determined respective time shift and determining a second seismocardiogram template, wherein the second template is based on the at least two time-shifted seismocardiograms.

The invention discloses a flexible ultrasonic patch for continuous monitoring of multi-dimensional physiological parameters of blood vessels, relates to the technical field of medical instruments, and utilizes a designed flexible ultrasonic array to extract high-resolution carotid artery wall velocity motion waveforms by parallelly collecting multi-channel data, so that the blood vessel multi-dimensional physiological parameters can be continuously monitored, and the blood vessel multi-dimensional physiological parameters can be continuously monitored. And signal delays among different array elements can be calculated to obtain local pulse wave velocities (PWV). Moreover, the speed waveform, the heart rate, the amplitude, the calculated PWV and other key physical parameters are jointly input into a PINN (Physical Information Neural Network) framework, and the cuff blood pressure is used as a gold standard for training. According to the method integrating physical information (PWV) and deep learning, the defects that a traditional physical model is too simplified and a pure black box model lacks generalization ability are overcome, and the blood pressure prediction result is more accurate and robust and has a physical basis.

1. The name of this design product: Pulse wave measuring instrument (active). 2. Purpose of this design product: This design product is used to measure pulse wave velocity. 3. The key design point of this appearance design product lies in the overall shape of the product. 4. The picture or photo that best illustrates the design points: Stereoscopic drawing 1.

The present invention discloses the use of the AP2A1 gene in the preparation of a product for the prevention and treatment of hypertension. The present invention found that AP2A1 expression levels were significantly elevated in hypertensive rat models. Further, inhibiting AP2A1 expression in these rat models significantly reduced abdominal aorta systolic and diastolic blood pressures, mean arterial pressure, vascular wall thickness, and pulse wave velocity, thereby improving the hypertensive phenotype. This indicates that AP2A1 has a role in regulating hypertension and can serve as a target, which is of great significance for the future development of drugs and the prevention and treatment of hypertension.

This invention belongs to the technical field of ischemic preconditioning training devices, specifically relating to a dual-airflow ischemic preconditioning training device and an intelligent training method. The training device includes modules for data acquisition, pressure setting, dual-airflow control, coordinated adjustment, and main control. It quantifies the physiological coupling degree by calculating the difference in blood pressure between the two arms and the pulse wave velocity, and simultaneously applies this coupling influence coefficient as a feedforward term and the coupling degree coefficient as a feedback parameter during the training period, thereby achieving adaptive and precise coordinated control of the two airflows. The method includes: acquiring basic physiological data and setting an initial target pressure individually; using a sliding mode control algorithm incorporating the physiological coupling term to track and stabilize the pressure in real time; and coordinating the adjustment of the target pressure in both arms based on the quantified coupling degree during the rest period. This invention effectively improves pressure control accuracy and training safety, enhances user experience, and enables personalized ischemic preconditioning training.

The invention discloses a pulse wave velocity measuring method, device and equipment and a medium. The measuring method comprises the following steps: acquiring an electrocardiogram signal of a heart; acquiring a pulse wave signal of any detection point of the body surface artery; performing second derivative operation on the pulse wave signal to obtain a pulse wave acceleration signal; according to the pulse wave acceleration signal and the electrocardiogram signal, the pulse wave propagation time difference from the heart to the detection point is determined; acquiring a curve distance from the heart to the detection point; calculating the ratio of the curve distance to the pulse wave propagation time difference to obtain the pulse wave speed. According to the method, the limitation that the traditional pulse wave speed must depend on synchronous measurement of two arteries is eliminated, the stable and reliable pulse wave speed can be obtained only through the single-point pulse wave signal and the electrocardiogram signal, and the multi-point detection requirement of the traditional method is avoided; and errors of single-point pulse wave measurement are made up by means of high time precision of the electrocardiogram signals, so that clinical credibility of pulse wave speed detection is guaranteed.

The present disclosure provides a method for estimating energetic hemodynamic parameters, including: an ultrasound device obtaining a vascular diameter and a blood flow waveform from a subject; obtaining a blood flow velocity of the subject; a processor providing a volumetric flow rate, a pulse wave velocity (PWV), and a blood pressure waveform of the subject; and a processor obtaining the energetic hemodynamic parameters. The present disclosure further provides a system for estimating energetic hemodynamic parameters, including: an ultrasound device having an ultrasound probe and used to obtain a vascular diameter and a blood flow waveform from a subject; and a processor coupled to the ultrasound device and used to perform the method of the present disclosure. The present disclosure still further provides a computer readable medium storing a computer executable code, upon executed, the computer executable code implements the method of the present disclosure.

The invention provides a system and a method for calculating a pulse wave velocity based on a plurality of intravascular ultrasonic pulses directed along a vessel. For each ultrasonic pulse, a plurality of echoes is received from a plurality of distances along the vessel. A first ultrasound Doppler signal is received from a first distance from the pulse origin and a second ultrasound Doppler signal from a second distance from the pulse origin. A first and second flow velocity metric is obtained based on the first and second ultrasound Doppler signal, respectively. The pulse wave velocity is calculated based on the time delay, which is based on the first flow velocity metric and the second flow velocity metric.

Properties of a blood vessel are determined by use of a laser Doppler vibrometer in which laser beams are directed to a patient or subject's skin over two regions, the chest and a superficial artery region (for example carotid neck region) where a pulse in an underlying blood vessel may be experienced. The pulse vibrations are detected by the vibrometer and their time of arrival at the regions determined. A time difference is calculated and from an understanding of the distance of the blood vessel travelled between the two regions a propagation speed or pulse wave velocity is calculated. The speed will vary in accordance with the stiffness or elasticity of the blood vessel. Thus, the condition of the blood vessel may be determined by calculating the stiffness (or elasticity) from the propagation speed.

An apparatus for measuring stiffness of a blood vessel such as an artery acquires a flow velocity waveform which is used to determine Natural Resonant Frequency and Pulse Wave Velocity for an arterial location. Pulse Wave Velocity is an established index of arterial stiffness while Natural Resonant Frequency is an index of arterial stiffness. The apparatus includes a flow velocity waveform detecting unit, a flow velocity and timing data extraction unit, and natural resonant frequency and pulse wave velocity determination units.